Core Insights - The long-term results from the SPYRAL HTN-ON MED trial indicate that the Symplicity Spyral renal denervation (RDN) procedure leads to significant and sustained reductions in blood pressure in patients on antihypertensive medications [1][2][3] Group 1: Clinical Trial Results - Patients treated with the Symplicity Spyral RDN system showed a reduction in 24-hour ambulatory systolic blood pressure (ABPM) of 14.0 mmHg compared to 9.3 mmHg in the sham group, with a treatment difference of 4.7 mmHg (p=0.0028) [4] - Office-based systolic blood pressure (OSBP) decreased by 18.5 mmHg in the RDN group versus 11.7 mmHg in the sham group, resulting in a treatment difference of 7.4 mmHg (p=0.0002) [4] - No renal artery stenosis greater than 70% was observed in the RDN group over three years, supporting the long-term safety of the procedure [2] Group 2: Study Overview - The SPYRAL HTN-ON MED trial is a global, randomized, sham-controlled study assessing the blood pressure-lowering effect and safety of the Symplicity RDN system in hypertensive patients prescribed up to three antihypertensive medications [3] - The study has involved over 5,000 patients and more than 30,000 procedures globally, establishing the Symplicity procedure as a standard in renal denervation [3] Group 3: Company Background - Medtronic plc, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges through innovative solutions [3] - The company employs over 95,000 people across more than 150 countries, providing technologies that treat 70 health conditions, including cardiac devices and surgical tools [3]